MIRA
INFORM REPORT
|
Report Date : |
28.03.2007 |
IDENTIFICATION
DETAILS
|
Name : |
SAURAV CHEMICALS LIMITED |
|
|
|
|
Registered Office : |
Village Saidpura, Derabassi-Barwala Road, Derabassi, Punjab |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2006 |
|
|
|
|
Date of Incorporation : |
20.12.1993 |
|
|
|
|
Com. Reg. No.: |
16-14017 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24112PB1993PLC014017 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
PTLS13480F |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AACCS4745B |
|
|
|
|
Legal Form : |
Closely held Public Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturing and Trading of Industrial Chemicals. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 300000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well-established and reputed company having satisfactory
track. Directors are reported as experienced and respectable businessmen. Trade
relations are reported as fair. Business is active. Payments are usually
correct and as per commitments. The company can be considered normal for business dealings at usual trade terms and conditions. |
LOCATIONS
|
Registered Office : |
Village Saidpura, Derabassi-Barwala Road, Derabassi, Punjab, India |
|
Tel. No.: |
91-1762-280334/ 522312 |
|
Fax No.: |
91-1762-280734/ 522313 |
|
E-Mail : |
|
|
|
|
|
Head Office : |
Plot No: 370,Industrial Area
Phase-II, Panchkula, Haryana |
|
Tel. No.: |
91-172-2595762[4 Lines] |
|
Fax No.: |
91-172-2595767 |
|
E-Mail : |
parveen@sauravchemicals.com,udsingh@sauravchemicals.com, purchases@sauravchemicals.com,
hr@sauravchemicals.com |
|
|
|
|
Factory 1 : |
Village Saidpura, Derabassi-Barwala Road, Derabassi, Punjab, India |
|
E-Mail : |
|
|
|
|
|
Branches : |
Located at : v New Delhi v Bangalore |
DIRECTORS
|
Name : |
Mr. Hari Chand Goyal |
|
Designation : |
Chairman |
|
Address : |
# 917, Sector 2, Panchkula |
|
Date of Birth/Age : |
15.02.1927 |
|
Date of Appointment : |
19.07.2001 |
|
|
|
|
Name : |
Mr. Praveen Goyal |
|
Designation : |
Managing Director |
|
Address : |
# 917, Sector 2, Panchkula |
|
Date of Birth/Age : |
08.02.1961 |
|
Date of Appointment : |
01.04.2002 |
|
|
|
|
Name : |
Mr. Udayan Sengupta |
|
Designation : |
Director |
|
Address : |
M-2/49, Model Town, Phase III, Delhi, India |
|
Date of Birth/Age : |
11.07.1960 |
|
Date of Appointment : |
01.08.2002 |
|
|
|
|
Name : |
Mr. Kripal Singh Pal |
|
Designation : |
Director |
|
Address : |
# H-82, Sarita Vihar, New Delhi, India |
|
Date of Birth/Age : |
15.02.1941 |
|
Date of Appointment : |
04.02.2004 |
|
|
|
|
Name : |
Mr. Avtar Singh |
|
Designation : |
Director |
|
Address : |
# 5411, Sector 38 (W), Chandigarh |
|
Date of Birth/Age : |
04.10.1958 |
|
Date of Appointment : |
01.08.2002 |
|
|
|
|
Name : |
Mrs. Kesro Devi |
|
Designation : |
Director |
|
Address : |
# 917, Sector 2, Panchakula |
|
Date of Birth/Age : |
10.06.1929 |
|
Date of Appointment : |
01.08.2003 |
|
|
|
|
Name : |
Mr. Sameer Saingla |
|
Designation : |
Director |
|
Address : |
# 9, Poorvi Marg, Vasant Vihar, New Delhi |
|
Date of Birth/Age : |
01.03.1974 |
|
Date of Appointment : |
01.08.2005 |
|
|
|
|
Name : |
Mr. Arun Kumar Mathur |
|
Designation : |
Director |
|
Address : |
# 138, Sector 35A, Chandigarh, India |
|
Date of Birth/Age : |
27.06.1948 |
|
Date of Appointment : |
19.09.2005 |
KEY EXECUTIVES
|
Name : |
Mr. Pradeep Kumar Chauhan |
|
Designation : |
Company Secretary |
|
Address : |
1223, Pushpac Complex, Sector 49-B, Chandigarh-160047, India |
|
Date of Birth/Age : |
01.02.1969 |
|
Date of Appointment : |
10.02.2006 |
MAJOR SHAREHOLDERS
/ SHAREHOLDING PATTERN
|
Names of Shareholders |
No. of Shares |
|
Ms. Neha Goyal |
19266 |
|
Mr. Saurav Goyal |
19266 |
|
Mr. Gaurav Goyal |
19266 |
|
Mr. Praveen Goyal & Sons (HUF) |
16770 |
|
Ms. Sunita Goyal |
50300 |
|
Mr. Sameer Singla |
97500 |
|
Mr. Udyan Sengupta |
17105 |
|
Mr. Praveen Goyal |
102632 |
|
Total |
342105 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturing and Trading of Industrial Chemicals. |
||||||
|
|
|
||||||
|
Products : |
|
PRODUCTION STATUS
|
Particulars |
Unit |
Licensed
Capacity |
Installed
Capacity |
Actual
Production |
|
Catalyst |
|
|
|
136.500 |
|
NCP |
Mts. |
|
|
0.889 |
|
Phenidone A |
Mts. |
|
|
-- |
|
PNBBr |
Mts. |
|
|
305.462 |
|
Phenyl Acetic Acid |
Mts. |
|
|
-- |
|
Hydrobbromic Acid -48% |
Mts. |
|
|
304.860 |
|
PNBA |
Mts. |
120.510 |
1341.310 |
10.501 |
|
AEB |
Mts. |
|
|
7.689 |
|
Butoxy Chloro Acetate |
Mts. |
|
|
69.015 |
|
Sodium Hypochlorite Solution |
Mts. |
|
|
1.449 |
|
Phthalamide FG |
Mts. |
|
|
4.706 |
|
Paranitro Tolune (rec) |
Mts. |
|
|
1.200 |
|
Sodium Hexonate |
Mts. |
|
|
24.293 |
|
Waste Solvent |
Mts. |
|
|
40.730 |
GENERAL
INFORMATION
|
Suppliers : |
v Tata Chemicals
Limited v Shub ham Thionyl
v Bayer Chemicals
AGD v Asian Industries v Bayer India
Limited v Captain
Chemicals v Chemical
Suppliers India Private Limited v Galaxy
Enterprises v Industrial
Agencies v Kudos Chemie
Limited v Kushal chemicals v N S Dyes &
Chemicals v Punjab Chemicals
& Pharma Limited v Pooja Chemicals v Solaris Chemtech
Limited v Sood Plastics
Private Limited v Syschem India
Limited v Trident Alco
Chem Limited v Trigon Gulf Fzco v United Traders v Bharat Sanchar
Nigam Limited v Sann Systems v Surinder Singh
Zrk v Aar Vee
Enterprises v Aggarwal
Electric Stores v Bombay Gujrat Road
Lines Private Limited v Bhandari Inter
State Carriers v Bharti Mobile
Limited |
||||||||||||||||||||
|
|
|
||||||||||||||||||||
|
Customers : |
v Parabolic Drugs
Limited v Kumar soaps
& Chemicals Limited v Morepan Lab
Limited, Baddi v Jai Mata Glass
Limited v Surya
Pharmaceuticals Limited, Baddi v Grauer & Well
India Limited v Aggarwal Soaps
& Chemicals v Vijay Paper Mart v Pfizer Limited v Group Chemicals v Adhesive (India) v Jagatjit
Industries Limited v Resinate Colours
Limited v Punjab Chemicals
& Pharmaceuticals Limited v Ranbaxy Lab
Limited, Toanse v Ind-Swift
Limited v Lupin
Laboratories Limited, Derra Bassi v Matrix
Laboratories Limited v Parabolic Drugs
Limited v Dhanuka
Laboratories Private Limited v Aurobindo Pharma
Limited v Cardkem Pharma
Private Limited v DSM Anti
Infectives India Private Limited v Granuels India
Limited v Natco Pharma
India Limited v Surya Medicare
Limited v Kudos Chemie
Limited v Pab Organicas
Private Limited v Biokem India v Saga Products v Floorex Tiles v Unimark Remedies
Limited |
||||||||||||||||||||
|
|
|
||||||||||||||||||||
|
No. of Employees : |
About 250 |
||||||||||||||||||||
|
|
|
||||||||||||||||||||
|
Bankers : |
State Bank of India, Industrial Estate, Chandigarh Branch Account No.30024228415 |
||||||||||||||||||||
|
|
|
||||||||||||||||||||
|
Facilities : |
Secured Loans
(Rs. In millions):
|
|
|
|
|
Banking
Relations : |
Satisfactory |
|
|
|
|
Auditors : |
|
|
Name : |
Kamal Kant Gambhir Chartered Accountants |
|
Address : |
S C O 201-2203, 3rd Floor, Sector 34B, Chandigarh-160022,
India |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
6000000 |
Equity Shares |
Rs.10/- each |
Rs.60.0000 millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
3157895 |
Equity Shares |
Rs.10/- each |
Rs.31.579 millions |
FINANCIAL DATA
[all figures are in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
31.579 |
30.000 |
30.000 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
47.265 |
31.078 |
17.630 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
78.844 |
61.078 |
47.630 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
138.259 |
94.318 |
16.974 |
|
|
2] Unsecured Loans |
20.268 |
20.254 |
11.730 |
|
|
TOTAL BORROWING |
158.527 |
114.572 |
28.704 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
0.000 |
1.147 |
|
|
|
|
|
|
|
|
TOTAL |
237.371 |
175.650 |
77.481 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
182.709 |
124.978 |
35.373 |
|
|
Capital work-in-progress |
1.770 |
32.002 |
14.137 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.000 |
0.000 |
0.000 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
17.939
|
14.769 |
9.379 |
|
|
Sundry Debtors |
56.250
|
55.865 |
35.424 |
|
|
Cash & Bank Balances |
3.302
|
4.347 |
4.056 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.114 |
|
|
Loans & Advances |
18.975
|
14.121 |
5.847 |
|
|
Securities |
0.000
|
0.000 |
1.151 |
|
Total
Current Assets |
96.466
|
89.102 |
55.971 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
31.649
|
57.899 |
18.136 |
|
|
Provisions |
12.045
|
12.713 |
10.332 |
|
Total
Current Liabilities |
43.694
|
70.612 |
28.468 |
|
|
Net Current Assets |
52.772
|
18.490 |
27.503 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.120 |
0.180 |
0.468 |
|
|
|
|
|
|
|
|
TOTAL |
237.371 |
175.650 |
77.481 |
|
PROFIT & LOSS
ACCOUNT
|
PARTICULARS |
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
|
Sales Turnover |
341.769 |
263.522 |
180.038 |
|
|
Other Income |
6.101 |
5.142 |
2.696 |
|
|
Total Income |
347.870 |
268.664 |
182.734 |
|
|
|
|
|
|
|
|
Profit/(Loss) Before Tax |
25.782 |
26.664 |
22.547 |
|
|
Provision for Taxation |
9.569 |
9.821 |
0.000 |
|
|
Profit/(Loss) After Tax |
16.213 |
16.843 |
22.547 |
|
|
|
|
|
|
|
|
Earnings in Foreign Currency : |
|
|
|
|
|
|
Export Earnings |
NA |
NA |
0.020 |
|
|
Other Earnings |
NA |
NA |
0.151 |
|
Total Earnings |
NA |
NA |
0.171 |
|
|
|
|
|
|
|
|
Imports : |
|
|
|
|
|
|
Raw Materials |
NA |
NA |
21.231 |
|
Total Imports |
NA |
NA |
21.231 |
|
|
|
|
|
|
|
|
Expenditures : |
|
|
|
|
|
|
Manufacturing Expenses |
NA |
NA |
35.877 |
|
|
Administrative Expenses |
NA |
NA |
8.294 |
|
|
Raw Material Consumed |
101.974 |
97.499 |
44.909 |
|
|
Purchases made for re-sale |
42.831 |
42.496 |
50.887 |
|
|
Salaries, Wages, Bonus, etc. |
33.712 |
19.554 |
12.224 |
|
|
Managerial Remuneration |
2.300 |
2.050 |
NA |
|
|
Payment to Auditors |
0.090 |
0.050 |
NA |
|
|
Financial Expenses |
13.152 |
5.990 |
3.239 |
|
|
Insurance Expenses |
1.435 |
0.756 |
NA |
|
|
Power & Fuel |
32.286 |
16.851 |
NA |
|
|
Depreciation & Amortization |
NA |
NA |
4.757 |
|
|
Other Expenditure |
94.308 |
56.754 |
NA |
|
Total Expenditure |
322.088 |
242.000 |
22.547 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
PAT / Total Income |
(%) |
4.66
|
6.27 |
12.34 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
7.41
|
9.92 |
12.34 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
9.23
|
12.45 |
24.68 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.33
|
0.44 |
0.47 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
2.56
|
3.03 |
1.20 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.21
|
1.26 |
1.97 |
LOCAL AGENCY
FURTHER INFORMATION
Notes on Accounts
:
Cash credit limits from Citi Bank, Sector 9, Chandigarh are secured
against mortgage/pledge of fixed assets and hypothecation of stocks of raw materials,
work in progress, finished goods and book debts of the company in addition the
personal guarantee of directors of the company namely Mr. Hari Chand Goyal and
Mr. Praveen Goyal. Also provided to the Bankers is nter corporate guarantee
towards loans taken by Pooja Chemicals. Similarly Pooja chemicals has provided
inter corporate guarantee in respect of loans taken by the company.
The provisions of section 217 (1)(e) of the Companies Act, 1956 are not
applicable to the company.
The company has raised a Term Loan of Rs.7.500 millions against a
sanctioned loan of Rs.42.500 millions from Citi Bank N.A. Sector 9, Chandigarh
to finance expansion of the New Project to be located at Village Bhagwanpur,
Tehsil Derra Bassi, District Patiala. The said loan is secured by way of 1st
charge on fixed assets to be installed in the project under expansion. The said
loan is also secured by way of 1st charge on the fixed assets of
unit located at Saidpura and 2nd charge on the hypothecation of
stocks of raw materials, work in progress, finished goods an Book debts of the
company in addition to the personal guarantee of directors of the company
namely Mr. Hari Chand Goyal and Mr. Praveen Goyal. The company has incurred a
sum of Rs.19.240 millions towards the cost of land, building, machinery,
electric installation and furniture and fixtures etc. as on the dte of Balance
Sheet. Balance amount has been paid by the company fro its internal
accruals/right issue/bonus issue.
Securities and Earnest Money with various departments includes a sum of
Rs.0.264 millions with Punjab Financial Corporation for purchase of a sick unit
i.e. Goldy Footwears Private Limited, Village Saidpura, Derra Bassi.
Maximum balances due to/ from the concerns in which the directors are
interested :
Pooja Chemicals, Chandigarh : Rs.20261100 millions
Dhruv Chem & Pharma Private Limited : Rs.5570770 millions
Saurav Chemicals : Rs.715150 millions
Sanco Products Private Limited : Rs.31000000 millions
During the year the company has made a Right issue to the existing
shareholders in the ratio of 2:1 at par. The issue was fully subscribed and a
sum of Rs. 4.000 millions was received as Equity share capital from existing
shareholders. Further company made a Bonus issue in the ratio of 4:1 out of the
General reserves available with the company. Total issue was Rs.24 millions.
(2400000 Equity Shares of Rs.10/- each fully paid).
The company has incurred a sum of Rs.1.600 millions for Research and
Development activities. The said expenditure includes Rs.1.500 millions toward
Research to Society for Innovation and Development Centre. Indian Institute of
Science Campus, Bangalore. The amount has been paid for doing Research work for
Development of Monoclonal Antibodies Balance sum of Rs.0.100 millions is
revenue expenditure.
Form 8 Particular for
creation or modification of charges
|
Name of the company |
SAURAV CHEMICALS LIMITED |
|
Presented By |
Mr.
Praveen Goyal, Managing Director |
|
1) Date and description of instrument creating the change |
Title deed register to State Bank of India, SCB, Industrial Estate, Phase II, Chandigarh Dated 26.11.2005 agreement of loan for overall limit |
|
2) Amount secured by the charge/amount owing on the securities of charge |
Corporate Loan : Rs.20.000 millions Fund Based Limit : Rs.52.500 millions Non Fund Based Limit : Rs.17.500 millions SCL Limit : Rs.10.500 millions Total Limit : Rs.105.000 millions |
|
3) Short particular of the property charged. If the property acquired is subject to charge, date of the acquired of the property should be given |
Term Loan : First exclusive charge on all the fixed and movable assets of Unit of the company. Working Capital : First charge on the entire current assets of Unit I of the company. Second charge on fixed assets of Unit No.1 |
|
4) Gist of the terms and conditions and extent and operation of the charge. |
Term Loan Agreement : Term Loan to be repaid in 16 quarterly installments of Rs.1.250 millions each starting form October 2007. Interest during implementation will be paid as and when levied. Interest at 0.75% below SBAR with minimum of 9.50%. Margin at 30% Operation of chrge : 100% Fund Based Limit : Margins Raw Materials and FG 25% Book Debts : 40% Interest at 0.75% below SBAR with minimum of 9.50% Operation of charge : 100% |
|
5) Name and Address and description of the person entitled to the charge. |
State Bank of India, SCB, Industrial Estate, Phase II, Chandigarh |
|
6) Date and brief description of instrument modifying the charge |
Nil |
|
7) Particulars of modifications specifying the terms and conditions or the extent of operations of the charge in which modification is made and the details of the modification. |
Nil |
Website Details :
SCL Group, consisting of Saurav Chemicals Limited, Pooja
chemicals, and SCL Biosciences division, is active in various knowledge based
industries, with its main focus on Bulk APIs and Pharmaceutical ingredients,
wherein they provide world class contract manufacturing and custom synthesis
facilities. SCL is also active in the Biotechnology Domain.
The SCL Group has two
manufacturing facilities located in North India (Dera Bassi). With its head
office located at Panchkula near the city of Chandigarh. SCL has offices in New
Delhi (International Business division), Bangalore (Biotechnology Division),
Hyderabad and Mumbai (marketing Offices).
Their main Business
Areas are:
v Manufacturing of Bulk APIs and Intermediates
v Custom
Manufacturing and Custom synthesis
v Trading
in APIs and Pharmaceutical Intermediates
v Biotechnology
Division:Custom Research in Antibodies, Recombinant Proteins, Elisa Kit
development, Multifuntional Microarrays, Oligoarays etc.
MANUFACTURING
Their infrastructure & technological capabilities
enable them to provide reliable process development and chemical manufacturing
services.They undertake the following:
v Manufacture
of bulk APIs and advanced Intermediates.
v Contract
and Toll Manufacturing
v Custom
Synthesis
v Process
development
v Scaling
up of pilot plant processes to commercial levels.
Location
Modern API and Intermediate Manufacturing facilities, at
three separate campuses covering around 15 acres near the city of Chandigarh
and 250 KM to the north of New Delhi, namely:
Unit 01 & 01A: Manufacturing Fine Chemicals and Advanced Intermediates.
Unit 03: cGMP compliant, US FDA approvable API
manufacturing facility.
API unit at Derabassi, Punjab
Equipment
PROCESS EQUIPMENT
v High
pressure glass lined reactors for Hydrogenation
v Glass
lined reactors from 1KL to 3KL.
v SS
reactors 630 ltr to 3 KL
v Centrifuges
36" & 48"
v Tray
driers 24 tray.
v Vacuum
tray driers 24 tray
v Powder
processing area consisting GMP compliant
- Shifter multi mill,
- Air jet mill,
- Octagonet Blender and
- e-sealing machine
UTILITY EQUIPMENT
v IBR
Boiler 3 Tons
v -20
Deg.C brine facility
v + 5
Deg.C Chilling plant
v Induced
draft cooling tower
v Air
compressor System.
v DI
water Plant, USP 26 Specifications
v Soft
water plant.
v Clean
room
v FG /
Intermediate storage facility below 25 deg C
E.T.P.
v Multiple
Effect Evaporator
v Saff
technology base sewage treatment plant.
v Double
chamber Incinerator for solid waste.
v Impervious
solid disposal facility with leached collection system.
QUALITY CONTROL
v Head
space GC
v Auto
Injector- HPLC
v UV
v FTIR
v UV
analyser
v Electronic
balances, centrifuges, and autoclaves
v Microbiological
Lab
v Stability
chambers
v
Chemical Expertise
They have expertise in a variety of chemical reactions.
Some of which are:
v Halogenations
– Bromination, Chlorination
v Hydrogenation
& other high pressure based reactions
v Friedel
Craft's Reactions.
v Schiff
base reaction
v Grignard's
Reactions.
v Esterification/Trans-Esterification.
v Cryogenic
Reactions.
v Ultra
Low vacuum Reactions
Working on the CRAMS Model SCL group offers world class
contract manufacturing and custom synthesis facilities.
Their USFDA approvable and cGMP obliging manufacturing facility can manufacture
bulk actives and drug intermediates following environment friendly processes.
SCL has been engaged in Contract manufacturing activities
for many years and enjoys a strong reputation with most of the big Indian
players like Ranbaxy Laboratories ltd., Lupin Laboratories ltd., Aurobindo and
Orchid Pharma. Their basic strength has always been their stringent quality
norms and strict adherence to timelines.
At SCL the custom synthesis services division (CSSD)
serves customer with capacities in -
Optimizing existing processes and new chemical processes.
v Ensuring
timely and cost effective delivery of products
v Synthesizing
quantities ranging from milligram to kilograms and guarantee client
confidentiality.
Because of their small size they offer very competitive
prices, fast delivery, high quality products and prompt quotations.
They look forward to proposals
for: -
Development of new products on Contract manufacturing/
Custom Synthesis basis for Pharmaceutical and Chemical Industry for
v APIs
v Intermediates
v Side
Chains &Specialty Chemicals
PRODUCTS
The following products are offered by their International Trading
Division. Some of them are from their Indian Principals and the rest are
manufactured in their own facilities.
APIs with DMF / COS or European Registered Drug Dossiers are suitably indicated
in brackets. Some of the products can also be offered with non infringing
process as claimed by the principals.
Anti Allergic
Cetrizine Di HCl (Drug Dossier available for Tablets)
Fexofenadine HCl (Drug Dossier available for Tablets)
Loratidine / Desloratadine
Antidiabetics / Antiobesity
Orlistat Pioglitazone
Repaglinide
Rosiglitazone
Anti Fungal/Dermatological
Amorolfine
Fluconazole (COS and DMF available)
Itraconazole (DMF available)
Ketoconazole (COS and DMF available)
Terbinafine (Drug Dossier available for Tablets)
Analgesic/Anti Inflammatory/Antipyretic
Benzocaine HCl
Drotaverine
Ibuprofen Powder and Granules (COS and DMF available)
Lidocaine HCL (DMF available)
Metamizole Mg / Na (DMF available)
Meloxicam (Drug Dossier available for 7.5 and 15 mg
Tablets)
Midazolam Base / HCl / Maleate (DMF available)
Paracetamol Powder and Granules (COS and DMF available)
Tramadol HCl
Anti Malarial
Chloroquine Sulphate/Phosphate
Hydroxychloroquine Sulphate
Quinine HCl / Sulphate (DMF available)
Anti Osteoporisis
Alendronate Sodium
Risedronate Sodium
Asthma / Respiratory
Budesonide
Fluticasone Propionate
Montelukast Sodium
Salbutamol Sulphate
Salmeterol Xinafoate
Erythromycin and its Salts
Theophylline Anhydrous (COS and DMF available)
Cardiovascular
Amlodipine Besylate (COS and DMF available)
Candesartan
Carvedilol (Drug Dossier available for Tablets)
Celeprolol
Cilazapril
Clopidogrel
Dobutamine HCL
Enalapril (COS and DMF available)
Fosinopril (DMF available)
Perindopril (Non-infringing process)
Pravastatin (COS and DMF available)
Quinapril
Ramipril (COS and DMF available)
Rosuvastatin Simvastatin
(COS and DMF available)
Telmisartan (Non-infringing process)
Valsartan (Non-infringing process)
Cefaclor (7-ACCA available)
Cefixime (Cefixime Methyl Ester available)
Candesartan (intermediates available) Coenzyme Q-10 (Solanesol 90%)
Fexofenadine
Lansoprazole / Omeprazole
Paracetamol (PAP and PNP)
Sumatriptan
Trandolapril
Tramadol
Venlafaxine
CNS
Alprazolam ( DMF and COS available)
Bromazepam (DMF available)
Carbidopa
Clonazepam ( DMF available)
Donepezil (Non-infringing process)
Gabapentine
Lorazepam (DMF available)
Olanzapine Form 5 (Non-infringing process)
Sertraline (Drug Dossier available for Tablets)
Sumatriptan Suiccinate
Venlafaxine HCl (DMF available, Drug Dossier for SR
Capsules)
Cephalosporins / Carbapenems
Cefaclor
Cefixime (COS awaited)
Cefepime (Non-infringing process)
Cefazolin Sodium (COS and DMF available)
Cefotaxime Sodium
Cefpodoxime Proxetil
Cefprozil
Cefradine
Cefuroxime Axetil (COS and DMF available)
Imipenem-Cilastatin
Meropenem
Gastro Intestinal Tract
Cisapride Monohydrate
Domperidone Base/Maleate (COS and DMF available)
Esomeprazole Magnesium / Sodium
Famotidine (COS and DMF available)
Lansoprazole Powder / Pellets (DMF available)
Loperamide
Omeprazole Powder / Pellets (COS and DMF available)
Pantoprazole Sodium / Pellets
Rabeprazole Sodium
Ranitidine HCL (COS and DMF available)
Macrolides and Anti Infectives
Azithromycin Monohydrate (Non-infringing process)
Clarithromycin (DMF available)
Ciprofloxacin HCL (COS and DMF available)
Enrofloxacin HCL
Furosemide (COS and DMF available)
Linezolid
Moxifloxacin
Roxithromycin (COS and DMF available)
Sulphamethoxazole (COS and DMF available)
Trimethoprim (COS and DMF available)
Oncological
Anastrozole (Drug Dossier available for Inj)
Carboplatin (Drug Dossier available for Inj)
Bicalutamide (Drug Dossier available for Tablets)
Daunorubicin (Drug Dossier will be shortly available)
Docetaxel (Drug Dossier can be made available on request)
Doxorubicin (Drug Dossier available for Inj)
Irinotecam (Drug Dossier available for Inj)
Oxaliplatin (Drug Dossier available for Inj)
Paclitaxel (Drug Dossier available)
Vinblastine Sulphate
Vincristine Sulphate
Others
Ethambutol HCL
Fenasteride (Drug Dossier available for Tablets)
Mycofinolate Mofetil
Tacrolimus
Tamsulosin (Drug Dossier available for Capsules)
They don't offer their products for the markets where the
patents are still applicable.
Other
Intermediates
4-nitro benzyl alcohol
Paranitrobenzyl bromide
4-nitro benzaldehyde
Potassium phthalimide
3-nitro benzylbromide
N-chloro phthalimide
1-acetoxy Ethyl bromide
4-nitro phthalimide
LOCATION FOR INQUIRIES IN MAIL ON
CMT REPORT
(Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l Anti-Money
Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals have
been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.43.59 |
|
UK Pound |
1 |
Rs.85.53 |
|
Euro |
1 |
Rs.58.14 |
SCORE & RATING
EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
4 |
|
--LIQUIDITY |
1~10 |
6 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
47 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|